Future clinical testing of BET inhibitors in high-risk medulloblastoma is clearly necessary to provide the ultimate proof of the usefulness of this therapeutic strategy for the treatment of this highly aggressive pediatric malignancy. This evidence concerns the gene DNER and medulloblastoma.